Sobi Eyes International Expansion With Growing Late-Stage Pipeline
Revenues Grew By 8% In 2020
Executive Summary
Sobi is extending its reach in international markets including Russia and China and expects its late-stage R&D pipeline to drive growth.
You may also be interested in...
Sobi Ramps Up In Rare Diseases With Apellis Deal
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
Sobi Pays $100m Upfront For Selecta Gout Drug
Swedish Orphan Biovitrum has taken a stake in Selecta and got access to SEL-212, which it is hoping will win a head-to-head trial against Horizon's Krystexxa, the gold standard for chronic refractory gout.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.